Liver’s Master MicroRNA: How miR-122 Shapes Fatty Liver Disease, Hepatitis and Cancer

Few molecules sit as close to the center of liver biology as microRNA-122. Accounting for roughly seventy percent of all microRNAs in the liver, this short non-coding RNA has long been known as a guardian of hepatic identity, fine-tuning gene expression programs that keep hepatocytes metabolically active and structurally intact. Now, a comprehensive review published in the Journal of Molecular Medicine has brought together experimental, clinical and molecular evidence to argue that miR-122 is not merely a liver-enriched RNA species, but a master regulator whose dysregulation threads through virtually every major form of liver disease, from fatty liver and viral hepatitis to acute injury and hepatocellular carcinoma.

The review, led by researchers at the Medical University of Warsaw together with collaborators at the University of Warsaw and Penn State College of Medicine, synthesizes findings from preclinical models, human cohorts and mechanistic studies across the full spectrum of hepatic pathology. Its central message is one of context: the direction in which miR-122 moves, whether up or down, depends critically on which biological compartment is measured and at what stage of disease. Hepatic expression of the microRNA tends to decline as disease progresses, while circulating levels rise with hepatocyte injury. Far from being contradictory, the authors argue, these opposing patterns reflect distinct biological processes and must be interpreted together for miR-122 to serve as a valid biomarker.

Nowhere is this more relevant than in metabolic dysfunction-associated fatty liver disease, or MAFLD, a condition now estimated to affect between twenty-five and thirty percent of the global population. The disease begins as simple steatosis and can progress to inflammatory steatohepatitis, fibrosis, cirrhosis and, ultimately, hepatocellular carcinoma or acute liver failure. In mouse models fed a high-fat diet and in hepatic cells exposed to free fatty acids, miR-122 expression rises, suppressing the metabolic sensor Sirt1 and thereby activating the lipogenic genes SREBP1, FASN, ACC1 and SCD1. Inhibiting miR-122 restores Sirt1, reactivates the downstream LKB1/AMPK energy-sensing pathway and reduces fat accumulation in liver cells, establishing the miR-122/Sirt1 axis as a key driver of hepatic lipogenesis.

Human studies reinforce this mechanistic picture. Early clinical work from 2011 showed that circulating miR-122, together with miR-34a, was substantially elevated in MAFLD patients compared with healthy controls, with levels increasing progressively as simple steatosis gave way to steatohepatitis and correlating with liver enzymes, fibrosis stage and inflammatory markers. In a Japanese cohort of sixty-seven patients in whom paired liver and serum samples were available, hepatic and circulating miR-122 levels tracked each other closely, yet the relationship with fibrosis proved stage-dependent: expression was higher in mild than in severe fibrosis. A separate longitudinal biopsy study found that changes in circulating miR-122 were linked to steatosis, ballooning degeneration and fibrosis over a median follow-up of 4.6 years. More recently, a 2025 systematic review of 1,149 studies identified miR-122 as the most frequently investigated circulating microRNA in MASLD, appearing in roughly thirty-six percent of studies and reaching diagnostic AUROCs of 0.81 to 1.0 for steatohepatitis.

The inflammatory dimension of the story connects the gut to the liver. In an Egyptian study of fifty MAFLD patients, fifty MASH patients and fifty healthy controls, blood-exosomal miR-122 and miR-128 were upregulated alongside the bacterial product LPS, its receptor TLR-4 and the transcription factor FoxO3, while adiponectin and several other microRNAs were downregulated. This LPS/TLR-4/FoxO3 signaling axis links gut microbial imbalance to hepatic inflammation and offers a mechanistic route by which miR-122 participates in the transition from fatty liver to inflammatory disease. Adipocyte-derived exosomes add another layer: these vesicles carry high levels of miR-122 into hepatocytes, where suppression of Sirt1 increases gluconeogenic and lipogenic enzymes, raises inflammatory cytokines such as TNF-alpha and IL-1beta, and reduces fat oxidation through PPARalpha.

In acute liver injury, miR-122 behaves as a sensitive gauge of hepatocyte damage. In acetaminophen-induced injury models, the drug increased liver necrosis, inflammation, serum transaminases and miR-122-5p expression, while a miR-122-5p suppressor partially reversed these effects through upregulation of the target gene NDRG3 and favorable shifts in apoptotic markers, increasing Bcl-w and Bcl-2 while decreasing Bax. In a clinical cohort of 223 critically ill patients, serum miR-122 was substantially elevated compared with healthy controls, correlated strongly with traditional injury markers including ALT, AST and GLDH, and persisted as an independent indicator of hepatocyte injury regardless of whether the underlying condition was septic or non-septic.

Viral hepatitis reveals the molecule’s most striking paradox. In hepatitis B virus infection, miR-122 acts as a natural antiviral factor: overexpression in hepatoma cells suppressed HBsAg, HBeAg and viral DNA by fifty to seventy percent, while inhibition doubled HBV mRNA levels. Clinically, serum miR-122 was lower in HBV patients than in controls and inversely correlated with viral load. Mechanistically, miR-122 downregulates cyclin G1, disrupting its interaction with p53 and thereby removing a pro-viral loop; it also induces the antiviral enzyme heme oxygenase-1. In hepatitis C, by contrast, miR-122 is essential for viral replication, binding the HCV genome and stabilizing it. Circulating miR-122 is nonetheless elevated in chronic HCV patients, correlates with disease severity independently of viral load, and its upregulation appears independent of viral genotype, holding across both genotype 1 and genotype 3 predominant populations.

In hepatocellular carcinoma, loss of miR-122 emerges as a key oncogenic event. Tumor tissue from 142 HBV-related liver cancers showed significantly reduced miR-122, and low expression correlated with larger tumors, venous invasion, poor differentiation and reduced overall survival. Multiple target axes explain the tumor-suppressive effect: derepression of NDRG3, PTTG1-binding factor, PEG10 and GALNT10 each contributes to tumor growth, invasion and progression, while the Hnf4alpha/miR-122/GALNT10 pathway links transcriptional dysregulation to oncogenic protein activity. Mice engineered to lack miR-122 develop dysregulated lipid metabolism, steatosis, fibrosis and spontaneous liver cancer with epithelial-mesenchymal features; reintroducing the microRNA reverses these defects. Notably, the regulation of miR-122 differs by etiology: in HBV-associated HCC, epigenetic silencing through a PPARgamma/RXRalpha complex, histone methylation by SUV39H1 and viral protein effects drive suppression, whereas in chronic HCV the reduction appears linked to the host interferon response.

The therapeutic history of anti-miR-122 drugs is a cautionary tale. Miravirsen, a locked nucleic acid-modified antisense oligonucleotide and the first anti-microRNA drug to enter human trials, produced dose-dependent and sustained reductions in HCV RNA in phase 2a studies. Yet development was discontinued after viral resistance emerged through mutations in the viral 5-prime untranslated region that permitted miR-122-independent replication, and after direct-acting antivirals achieved cure rates above ninety-five percent, rendering a host-targeted strategy largely redundant. The GalNAc-conjugated antagomir RG-101 achieved marked viral-load reductions, including sustained virological responses after a single dose, but was placed on FDA clinical hold in 2016 following cases of severe hyperbilirubinemia attributed to inhibition of the MRP2 bilirubin transporter combined with preferential uptake into hepatocytes. Beyond these specific liabilities lies a more fundamental concern: because miR-122 is a tumor suppressor whose loss drives steatosis, fibrosis and cancer, sustained systemic suppression carries a theoretical long-term oncogenic risk.

The review’s authors conclude that the future of miR-122 lies in restoration rather than inhibition, particularly for metabolic and neoplastic liver disease, and in its use as a minimally invasive biomarker within multi-marker panels rather than as a standalone diagnostic. Given its high sensitivity to hepatocellular injury but limited disease specificity, serial measurement of circulating miR-122, ideally alongside other microRNAs and conventional markers, is likely to outperform any single-timepoint reading. A longitudinal study of eighty-one Japanese MAFLD patients illustrates the prognostic potential: among patients with persistent severe fibrosis, those who later developed liver cancer had significantly lower miR-122 levels, and a miR-122 ratio below 0.5 predicted higher cancer incidence and poorer survival. Standardized assays, longitudinal multi-omics studies and well-designed trials of miR-122-restoring strategies, the authors argue, are the necessary next steps to translate two decades of mechanistic insight into clinical benefit for the hundreds of millions of people living with liver disease worldwide.

Subject of Research: The role of microRNA-122 as a regulator and biomarker of liver disease

Article Title: MicroRNA-122 as a regulator and biomarker of liver disease

Article References: Ahmadova, S., Wicik, Z., Mucha, J., Palatini, J., Ziętal, K., Mirowska-Guzel, D., Przybylkowski, A., & Eyileten, C. (2026). MicroRNA-122 as a regulator and biomarker of liver disease. Journal of Molecular Medicine, 104(1), Article 110. https://doi.org/10.1007/s00109-026-02718-1

Image Credits: AI Generated

DOI: 10.1007/s00109-026-02718-1

Keywords: microRNA-122, liver disease, MAFLD, MASH, hepatitis B, hepatitis C, hepatocellular carcinoma, biomarker, fibrosis, lipid metabolism, antiviral therapy, miravirsen